471820 — Cellromax Science Co Income Statement
0.000.00%
Last trade - 00:00- KR₩61bn
- KR₩49bn
- KR₩22bn
- 73
- 53
- 26
- 50
Annual income statement for Cellromax Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 18,837 | 21,086 | 19,310 | 21,630 |
| Cost of Revenue | ||||
| Gross Profit | 8,783 | 9,853 | 9,755 | 12,284 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 13,728 | 14,476 | 14,689 | 16,126 |
| Operating Profit | 5,110 | 6,610 | 4,621 | 5,505 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 5,035 | 5,938 | 5,655 | 5,136 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 3,984 | 4,732 | 4,499 | 3,817 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 3,984 | 4,732 | 4,499 | 3,817 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 3,984 | 4,732 | 4,499 | 3,817 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 342 | 406 | 390 | 366 |
| Dividends per Share |